Replies to post #3312 on Nexien BioPharma Inc (NXEN)

[surfgreen]

Only chance fro a rebound is a merger or acquisition. Company has value and patents and a fantastic share structure with no debt or toxic notes. Very low burn rate -Executives are not getting paid just in shares.

[Renegades17]

The plan sounded good

But the execution, or lack thereof, has been poor. In addition, the market backdrop isn't as supportive as I once suspected. The FDA is highly skeptical of CBD at this point, so it's going to take years of research and trials to bring drugs to market.

NXEN's best chance to make it as a business is to focus on international markets like Western Europe and Israel, but the latter is small. That said, as one of the other posters suggested, the best outcome for shareholders is a sale to monetize whatever value exists in the patent portfolio and XactDose.